{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:33:16Z","timestamp":1790249596428,"version":"4.1.0"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-ioi260007-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Injection drug use is a major risk factor for both hepatitis C virus (HCV) infection and incarceration. The high volume and rapid turnover of individuals in jails make this setting a critical access point for hepatitis C elimination among people who inject drugs, with potential downstream benefits for reducing community transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the health benefits, costs, and cost-effectiveness of jail-based HCV interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cost-effectiveness analysis extended a dynamic network simulation model of HCV transmission through injection equipment sharing among people who inject drugs to incorporate population transitions between jails and communities. Data on justice-involved individuals from the Philadelphia FIGHT program and published literature on people who inject drugs in urban settings in the US were used to model an urban correctional and community setting. Analyses were conducted between April 2024 and February 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-7\">\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Jail-based HCV interventions comprising varying combinations of testing at entry, treatment in jail, and HCV navigation services on release.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Changes in person-years of HCV infection, incidence of HCV infection, HCV-related mortality, cumulative quality-adjusted life-years (QALYs), and health care costs across 60 years, and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean initial age of 1552 simulated people who inject drugs was 32 years. Without jail-based interventions, there were 21\u202f349 person-years of infection, 662 incident infections, and 240 HCV-related deaths per 1000 people who inject drugs over the 60-year time horizon. The combined strategy of testing and treatment plus navigation reduced the cumulative person-years of infection, incidence, and HCV-related deaths in the simulated population by 35% (95% UI, 30%-39%), 47% (95% UI, 41%-54%), and 40% (95% UI, 31%-49%), respectively. The ICER of this strategy was $11\u202f000 per QALY gained compared with no jail-based intervention, well below typical standards for benchmarking cost-effectiveness, which often use thresholds ranging from $50\u202f000 to $150\u202f000 per QALY gained. Providing treatment in jails in addition to testing was cost-saving or yielded lower ICERs compared with providing only testing. Strategies that incorporated navigation yielded lower ICERs than strategies that did not. The results were robust to variations in key parameter values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260007-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cost-effectiveness analysis using a network simulation model, jail-based HCV elimination interventions, particularly those providing treatment during detention, reduced prevalent and incident HCV cases and HCV-related deaths among people who inject drugs both within and beyond jails. These interventions are a cost-effective strategy for public health decision-makers to consider.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.0190","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:30:27Z","timestamp":1774279827000},"page":"585","source":"Crossref","is-referenced-by-count":4,"title":["Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies"],"prefix":"10.1001","volume":"186","author":[{"given":"Lin","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"},{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora N.","family":"Magaldi","sequence":"additional","affiliation":[{"name":"Philadelphia FIGHT, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani A.","family":"Wagh","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza R.","family":"Ennis","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa B.","family":"Reitsma","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica E.","family":"Kuncio","sequence":"additional","affiliation":[{"name":"Philadelphia Department of Public Health, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Addish","sequence":"additional","affiliation":[{"name":"Philadelphia Department of Public Health, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy R.","family":"Varghese","sequence":"additional","affiliation":[{"name":"Curran-Fromhold Correctional Facility, Philadelphia Department of Prisons, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Furukawa","sequence":"additional","affiliation":[{"name":"National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Honeycutt","sequence":"additional","affiliation":[{"name":"National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Chen","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Salomon","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ioi260007r3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017-March 2020.","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ioi260007r4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2468-1253(23)00082-1","article-title":"The road to HIV and HCV elimination among people who inject drugs.","volume":"8","author":"Corona-Mata","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ioi260007r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100178","article-title":"Hepatitis C virus care cascade among people who inject drugs in Puerto Rico: minimal HCV treatment and substantial barriers to HCV care.","volume":"8","author":"Aponte-Mel\u00e9ndez","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"ioi260007r6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct J"},{"issue":"1","key":"ioi260007r10","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000117","article-title":"The hepatitis C care cascade in California state prisons: screening and treatment scale-up and progress toward elimination, 2016-2023.","volume":"23","author":"Lucas","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"23","key":"ioi260007r12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers.","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi260007r16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis.","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"ioi260007r18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx142","article-title":"Feasibility of treating hepatitis C in a transient jail population.","volume":"4","author":"MacDonald","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"ioi260007r21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa377","article-title":"Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents.","volume":"7","author":"Norton","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"ioi260007r23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"ioi260007r27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa263","article-title":"Outcomes of hepatitis C virus treatment in the New York City jail population: successes and challenges facing scale up of care.","volume":"7","author":"Chan","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"ioi260007r28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40352-017-0055-0","article-title":"The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care.","volume":"5","author":"Hochstatter","year":"2017","journal-title":"Health Justice"},{"issue":"2","key":"ioi260007r29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA.","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"issue":"32","key":"ioi260007r30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: hepatitis C treatment among insured adults\u2014United States, 2019\u20132020.","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"ioi260007r31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac350","article-title":"Care navigation increases initiation of hepatitis C treatment after release from prison in a prospective randomized controlled trial: the C-LINK Study.","volume":"9","author":"Papaluca","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"ioi260007r32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12879-019-4344-1","article-title":"Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial.","volume":"19","author":"Akiyama","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"4","key":"ioi260007r33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.gastre.2021.09.006","article-title":"Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Influencia de los trastornos psiqui\u00e1tricos y la terapia de sustituci\u00f3n con opi\u00e1ceos en el tratamiento del virus de la hepatitis C con antivirales de acci\u00f3n directa en usuarios de drogas por v\u00eda parenteral.","volume":"45","author":"Fern\u00e1ndez de Ca\u00f1ete Camacho","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"ioi260007r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100567","article-title":"The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017.","volume":"27","author":"Chan","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"ioi260007r35","doi-asserted-by":"publisher","first-page":"e2338792","DOI":"10.1001\/jamanetworkopen.2023.38792","article-title":"Community-based point-of-diagnosis hepatitis C treatment for marginalized populations: a nonrandomized controlled trial.","volume":"6","author":"Morris","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ioi260007r36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/infdis\/jiaa017","article-title":"Human immunodeficiency virus and hepatitis C virus infection testing among commercially insured persons who inject drugs, United States, 2010\u20132017.","volume":"222","author":"Bull-Otterson","year":"2020","journal-title":"J Infect Dis"},{"issue":"42","key":"ioi260007r37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.15585\/mmwr.mm7042a1","article-title":"HIV infection and HIV-associated behaviors among persons who inject drugs\u201423 metropolitan statistical areas, United States, 2018.","volume":"70","author":"Handanagic","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"ioi260007r38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/hep.27584","article-title":"The continuum of hepatitis C testing and care.","volume":"61","author":"Viner","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"ioi260007r39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jvh.12506","article-title":"Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.","volume":"23","author":"Younossi","year":"2016","journal-title":"J Viral Hepat"},{"issue":"7","key":"ioi260007r40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/jvh.13274","article-title":"Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.","volume":"27","author":"Falade-Nwulia","year":"2020","journal-title":"J Viral Hepat"},{"key":"ioi260007r41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/00333549161310S210","article-title":"Efforts at the frontlines: implementing a hepatitis C testing and linkage-to-care program at the local public health level.","volume":"131","author":"Se\u00f1a","year":"2016","journal-title":"Public Health Rep"},{"issue":"6","key":"ioi260007r42","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy120","article-title":"Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting.","volume":"5","author":"Alimohammadi","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"ioi260007r43","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis.","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ioi260007r45","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"5","key":"ioi260007r46","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"ioi260007r47","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"ioi260007r48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"8","key":"ioi260007r49","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/j.1360-0443.2008.02153.x","article-title":"Preference-weighted health-related quality of life measures and substance use disorder severity.","volume":"103","author":"Pyne","year":"2008","journal-title":"Addiction"},{"issue":"1","key":"ioi260007r50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","article-title":"A systematic review and meta-analysis of health utilities in patients with chronic hepatitis C.","volume":"23","author":"Saeed","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"ioi260007r51","first-page":"526","article-title":"Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.","volume":"24","author":"McCollister","year":"2018","journal-title":"Am J Manag Care"},{"issue":"2","key":"ioi260007r52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine\u2013naloxone versus extended-release naltrexone to prevent opioid relapse.","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann Intern Med"},{"key":"ioi260007r53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA Clinical Trials Network CTN-0051, extended-release naltrexone vs. buprenorphine for opioid treatment (X: BOT): study design and rationale.","volume":"50","author":"Lee","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"ioi260007r54","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value Health"},{"issue":"7","key":"ioi260007r55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.","volume":"17","author":"McAdam-Marx","year":"2011","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"ioi260007r56","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population.","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"ioi260007r58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.drugalcdep.2017.11.031","article-title":"Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.","volume":"185","author":"Schackman","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"ioi260007r62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216205","article-title":"Estimated cost of comprehensive syringe service program in the United States.","volume":"14","author":"Teshale","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"ioi260007r63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder.","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ioi260007r64","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf368","article-title":"Potential impact of frequent testing for hepatitis C virus among people who inject drugs toward hepatitis C elimination in the United States.","author":"Zhu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"ioi260007r65","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.1870","article-title":"Health and economic impact of periodic hepatitis C virus testing among people who inject drugs.","author":"Zhu","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ioi260007r66","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104539","article-title":"Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study.","volume":"130","author":"Zhu","year":"2024","journal-title":"Int J Drug Policy"},{"key":"ioi260007r67","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaf052","article-title":"Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation.","author":"Zhu","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"4","key":"ioi260007r68","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0272989X9701700414","article-title":"Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means.","volume":"17","author":"Stinnett","year":"1997","journal-title":"Med Decis Making"},{"issue":"5","key":"ioi260007r69","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"27","key":"ioi260007r70","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1056\/NEJMp1512009","article-title":"Measuring the value of prescription drugs.","volume":"373","author":"Neumann","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi260007r71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1353\/hpu.2023.a903067","article-title":"Incarceration, inequality, and hepatitis C treatment: the story of two Southern states.","volume":"34","author":"Wennerstrom","year":"2023","journal-title":"J Health Care Poor Underserved"},{"issue":"3","key":"ioi260007r72","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/00952990.2021.1995402","article-title":"Polysubstance use and re-incarceration in the 12-months after release from jail: a latent transition analysis of rural Appalachian women.","volume":"48","author":"Bunting","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"ioi260007r73","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/add.12938","article-title":"Incarceration and injection drug use in Baltimore, Maryland.","volume":"110","author":"Genberg","year":"2015","journal-title":"Addiction"},{"issue":"6","key":"ioi260007r74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/aje\/kwr327","article-title":"Risks of drug-related death, suicide, and homicide during the immediate post-release period among people released from New York City jails, 2001-2005.","volume":"175","author":"Lim","year":"2012","journal-title":"Am J Epidemiol"},{"key":"ioi260007r19","volume-title":"Staff Shortages in Prisons and Jails Highlight Opportunities for Decarceration","author":"LeMasters","year":"2022"},{"key":"ioi260007r1","unstructured":"Office of Infectious Disease and HIV\/AIDS Policy. Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021\u20132025). Accessed October 9, 2024. https:\/\/www.hhs.gov\/hepatitis\/viral-hepatitis-national-strategic-plan\/index.html"},{"key":"ioi260007r2","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance report \u2014 United States, 2023. Accessed May 9, 2025. https:\/\/www.cdc.gov\/hepatitis-surveillance-2023\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/hepatitis\/statistics\/2022surveillance\/index.htm"},{"key":"ioi260007r7","unstructured":"Widra? E. Addicted to punishment: jails and prisons punish drug use far more than they treat it. Prison Policy Initiative. January 30, 2024. Accessed October 9, 2024. https:\/\/www.prisonpolicy.org\/blog\/2024\/01\/30\/punishing-drug-use\/"},{"key":"ioi260007r8","unstructured":"Substance Abuse and Mental Health Services Administration. 2022 National Survey on Drug Use and Health (NSDUH) Releases. 2023. Accessed October 9, 2024. https:\/\/www.samhsa.gov\/data\/release\/2022-national-survey-drug-use-and-health-nsduh-releases"},{"key":"ioi260007r9","unstructured":"Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among persons who inject drugs\u2014national HIV behavioral surveillance: injection drug use, 20 US cities, 2022. Published February 1, 2024. Accessed October 9, 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/150464"},{"key":"ioi260007r11","unstructured":"Hepatitis Education Project. Prevention + treatment for viral hepatitis. Accessed October 9, 2024. https:\/\/hep.org\/"},{"key":"ioi260007r13","unstructured":"Interreg Europe. Good practices: Jailfree C. Published July 26, 2021. Accessed October 9, 2024. https:\/\/www.interregeurope.eu\/good-practices\/jailfree-c#"},{"key":"ioi260007r14","unstructured":"Bureau of Justice Statistics. Jail inmates in 2023\u2014statistical tables. April 2025. Accessed July 28, 2025. https:\/\/bjs.ojp.gov\/web-report\/jail-inmates-2023-statistical-tables"},{"key":"ioi260007r15","unstructured":"International Network on Hepatitis in Substance Users. Hepatitis C care navigation. March 20, 2023. Accessed October 9, 2024. https:\/\/www.inhsu.org\/intervention\/hepatitis-c-care-navigation\/"},{"key":"ioi260007r17","unstructured":"Philadelphia FIGHT community health center. Annual report 2018. Accessed October 9, 2024. https:\/\/fight.org\/wp-content\/uploads\/2019\/05\/FIGHT_AnnualReport_2018.pdf"},{"key":"ioi260007r20","unstructured":"Strick? LB, Corcorran? MA. Treatment of HCV in a correctional setting. January 25, 2024. Accessed September 22, 2025. https:\/\/www.hepatitisc.uw.edu\/go\/key-populations-situations\/treatment-corrections\/core-concept\/all"},{"key":"ioi260007r22","unstructured":"Canzater? SL. Correctional institutions are a critical intervention point for hepatitis C elimination. March 30, 2020. Accessed July 29, 2025. https:\/\/oneill.law.georgetown.edu\/publications\/correctional-institutions-are-a-critical-intervention-point-for-hepatitis-c-elimination\/"},{"key":"ioi260007r24","unstructured":"Trooskin? S, Allen? E, Anderson? J, . Implementation of routine opt out hepatitis c testing in the Philadelphia jail system. 2021. Accessed November 15, 2024. https:\/\/www.natap.org\/2021\/AASLD\/AASLD_124.htm"},{"key":"ioi260007r25","unstructured":"City of Philadelphia Department of Public Health. Ongoing HIV risk behaviors in Philadelphia: data from the National HIV Behavioral Surveillance (NHBS) System, 2018. Accessed March 3, 2025. https:\/\/www.phila.gov\/media\/20210311114659\/IDU5-Fact-Sheet-Released-03.11.2021.pdf"},{"key":"ioi260007r26","unstructured":"Zeng? Z. Jail inmates in 2022 \u2014 statistical tables. December 2023. Accessed November 14, 2024. https:\/\/bjs.ojp.gov\/library\/publications\/jail-inmates-2022-statistical-tables"},{"key":"ioi260007r44","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on drug use and health. 2021. Accessed April 22, 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR102121.htm"},{"key":"ioi260007r57","unstructured":"Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2025. Accessed January 4, 2025. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs"},{"key":"ioi260007r59","unstructured":"American Association for the Study of Liver Diseases. Simplified HCV treatment for treatment-naive adults without cirrhosis. Updated October 24, 2022. Accessed January 4, 2025. https:\/\/www.hcvguidelines.org\/treatment-naive\/simplified-treatment"},{"key":"ioi260007r60","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule. 2025. Accessed January 4, 2025. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician"},{"key":"ioi260007r61","unstructured":"Office of Procurement Acquisition and Logistics (OPAL). Pharmaceutical pricing data. Federal Supply Schedule. 2025. Accessed January 4, 2025. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmPrices.asp"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2846745\/jamainternal_zhu_2026_oi_260007_1777045080.61423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:01:50Z","timestamp":1777906910000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2846745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.0190","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}